Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CARM1 | Q86X55 | 16/20 | 0.67 |
| ▸ | PRMT6 | Q96LA8 | 16/20 | 0.67 |
| ▸ | PRMT8 | Q9NR22 | 3/20 | 0.67 |
| ▸ | PRMT1 | Q99873 | 1/20 | 0.67 |
| ▸ | TMEM97 | Q5BJF2 | 1/20 | 0.45 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.45 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12352567 | 0.88 | CARM1 (0.57) | CARM1PRMT6PRMT8PRMT1 | |
| SCHEMBL12477864 | 0.88 | CARM1 (0.57) | CARM1PRMT6PRMT8PRMT1 | |
| SCHEMBL11992320 | 0.88 | CARM1 (0.57) | CARM1PRMT6PRMT8PRMT1 | |
| SCHEMBL14272558 | 0.88 | CARM1 (0.52) | CARM1PRMT6PRMT8PRMT1 | |
| SCHEMBL26495258 | 0.86 | CARM1 (0.50) | CARM1PRMT6PRMT8PRMT1 | |
| SCHEMBL26495337 | 0.84 | CARM1 (0.48) | CARM1PRMT6PRMT8PRMT1SIGMAR1 | |
| SCHEMBL26494036 | 0.84 | CARM1 (0.48) | CARM1PRMT6PRMT8PRMT1SIGMAR1 | |
| SCHEMBL16020344 | 0.80 | CARM1 (1.00) | CARM1PRMT6PRMT8PRMT1TMEM97 | |
| SCHEMBL14033404 | 0.80 | CARM1 (0.69) | CARM1PRMT6PRMT8PRMT1TMEM97 | |
| SCHEMBL13178527 | 0.79 | PRMT6 (0.51) | CARM1PRMT6PRMT8PRMT1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 50 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4328227-A1 | NUCLEOSIDE COMPOUND AND APPLICATION THEREOF IN THE TREATMENT OF FELINE INFECTIOUS PERITONITIS | Vigonvita Life Sciences Co., Ltd. (CN) | 2024-02-28 | — | — | EP | disclosed |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | US | disclosed |
| WO-2023196444-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | CAPSTAN THERAPEUTICS, INC. (US) | 2023-10-12 | — | — | WO | disclosed |
| WO-2021146629-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC. (US) | 2021-07-22 | — | — | WO | disclosed |
| EP-3831824-A1 | PREPARATION AND APPLICATION OF CLASS OF N-CONTAINING HETEROCYCLIC COMPOUNDS HAVING IMMUNOREGULATORY FUNCTION | Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) | 2021-06-09 | — | — | EP | disclosed |
| EP-3831823-A1 | PREPARATION AND APPLICATION OF AROMATIC COMPOUND HAVING IMMUNOREGULATORY FUNCTION | Shanghai Ennovabio Pharmaceuticals Co., Ltd. (CN) | 2021-06-09 | — | — | EP | disclosed |
| WO-2020160175-A1 | QUINDOLINE COMPOUNDS AND USES THEREOF | ARIZONA BOARD OF REGENTS ON BEHALF OF THE UNIVERSITY OF ARIZONA (US) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020160174-A1 | USES OF COMPOUNDS HAVING ANTI-HSV-1 ACTIVITY | UNIVERSITA DEGLI STUDI DI PADOVA (IT) | 2020-08-06 | — | — | WO | disclosed |
| WO-2020150674-A1 | HETEROCYCLIC COMPOUNDS AS ADENOSINE ANTAGONISTS | NUVATION BIO INC. (US) | 2020-07-23 | — | — | WO | disclosed |
| WO-2020024997-A1 | PREPARATION AND APPLICATION OF CLASS OF N-CONTAINING HETEROCYCLIC COMPOUNDS HAVING IMMUNOREGULATORY FUNCTION | 上海轶诺药业有限公司 | 2020-02-06 | — | — | WO | disclosed |
| US-20080200465-A1 | Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-08-21 | — | — | US | disclosed |
| US-7348427-B2 | Antipathogenic benzamide compounds | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-03-25 | — | — | US | disclosed |
| US-7329765-B2 | Benzothiophene compounds having antiinfective activity | GENESOFT PHARMACEUTICALS, INC. (US) | 2008-02-12 | — | — | US | disclosed |
| US-20080027037-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. | 2008-01-31 | — | — | US | disclosed |
| US-20080027037-A1 | Cyclic compounds | TANABE SEIYAKU CO., LTD. | 2008-01-31 | — | — | US | disclosed |
| US-7273868-B2 | Pyrazine derivatives | TANABE SEIYAKU CO., LTD. (JP) | 2007-09-25 | — | — | US | disclosed |
| US-7273868-B2 | Pyrazine derivatives | TANABE SEIYAKU CO., LTD. (JP) | 2007-09-25 | — | — | US | disclosed |
| US-7220736-B2 | Pyrimidine compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| US-7220736-B2 | Pyrimidine compounds | TANABE SEIYAKU CO., LTD. (JP) | 2007-05-22 | — | — | US | disclosed |
| EP-1277741-A1 | CYCLIC COMPOUNDS | TANABE SEIYAKU CO., LTD. (JP) | 2003-01-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080200465-A1 | Substituted with a morpholine group through amido heterocylic groups; interfering with the expression of genes essential for the pathogen's proliferation; treating viral and protozoan infections in mammals | IRF3, BCL3, L3MBTL3 | CARM1 388/4885PRMT6 1279/4885PRMT8 1861/4885 |
| US-20230320995-A1 | IONIZABLE CATIONIC LIPIDS AND LIPID NANOPARTICLES | PLTP, LNPEP, PLIN3 | CARM1 3427/4885PRMT6 3265/4885PRMT8 3449/4885 |
| US-20080027037-A1 | Cyclic compounds | PDE4A, PDE4B, PDE3B | CARM1 262/4885PRMT6 456/4885PRMT8 415/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.